bs-5913R

[Primary Antibody]

Calreticulin Rabbit pAb



www.bioss.com.cn sales@bioss.com.cn techsupport@bioss.com.cn 400-901-9800

		400-901-9800
Host: Rabbit	Isotype: IgG	Applications: WB (1:500-2000)
Clonality: Polyclonal		IHC-P (1:100-500) IHC-F (1:100-500)
GenelD: 811	SWISS: P27797	IF (1:100-500)
Target: Calreticulin		ELISA (1:5000-10000)
Immunogen: KLH conjugated synthetic peptide derived from human Calreticulin: 101-200/417.		Reactivity: Human
Purification: affinity purified by	Protein A	
Concentration: 1mg/ml		Predicted
Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.		MW.: ^{44 kDa}
Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.		Subcellular Secreted ,Extracellular Location: matrix ,Cell membrane
Background: Calreticulin is a hig primarily in the en of cellular process functions in protei Calreticulin is also have a role in tran erythematosus is against calreticulin	shly conserved chaperone protein which resides doplasmic reticulum, and is involved in a variety es, among them, cell adhesion. Additionally, it n folding quality control and calcium homeostasis found in the nucleus, suggesting that it may scription regulation. Systemic lupus associated with increased autoantibody titers h. Recurrent mutations in calreticulin have been	,Cytoplasm

- VALIDATION IMAGES -



Sample: Lane 1: Human Jurkat cell lysates Lane 2: Human HepG2 cell lysates Lane 3: Human MCF-7 cell lysates Primary: Anti-Calreticulin (bs-5913R) at 1/1000 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 44 kDa Observed band size: 52 kDa



linked to various neoplasms, including the myeloproliferative

type.[provided by RefSeq, May 2020]

Paraformaldehyde-fixed, paraffin embedded Human Kidney; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with Calreticulin Polyclonal Antibody, Unconjugated (bs-5913R) at 1:200 overnight at 4°C, followed by conjugation to the bs-0295G-HRP and DAB (C-0010) staining.



Paraformaldehyde-fixed, paraffin embedded Human Cerebrum; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with Calreticulin Polyclonal Antibody, Unconjugated (bs-5913R) at 1:200 overnight at 4°C, followed by conjugation to the bs-0295G-HRP and DAB (C-0010) staining.

- SELECTED CITATIONS -

- [IF=29.4] Zhenyu Wang. et al. Laser-Activatable in Situ Vaccine Enhances Cancer-Immunity Cycle. ADV MATER. 2023 Nov;:2307193 FCM ;Mouse. 37951210
- [IF=27.4] Qianyi Su. et al. Eradication of Large Tumors by Nanoscale Drug Self-Assembly. ADV MATER. 2024 Oct;:2410536 FC ;MOUSE. 39420689
- **[IF=27.4]** Ying-Tao Zhong. et al.Plasma Membrane Targeted Photodynamic Nanoagonist to Potentiate Immune Checkpoint Blockade Therapy by Initiating Tumor Cell Pyroptosis and Depleting Infiltrating B Cells.ADVANCED MATERIALS.2025 Feb 26:e2415078. IF,flow cytometry ;Mouse. 40012447
- [IF=18.9] Ze Wang. et al. Turning foes to friends: Advanced "in situ nanovaccine" with dual immunoregulation for

enhanced immunotherapy of metastatic triple-negative breast cancer. BIOACT MATER. 2024 Sep;39:612 FCM ;Mouse. 38883315

• [IF=18.5] Baohua Zhang. et al.Self-Oxygenated Biomimetic Nanozyme for Tumor Catalytic Immunotherapy.ADVANCED FUNCTIONAL MATERIALS.2025 Jan Flow cytometry ;Murine.